Immunosuppressants Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Immunosuppressants Market by Drug Class (Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others), by Indication (Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global immunosuppressants market size expected to reach $41,511.37 million by 2026, at a CAGR of 14.2% during forecast period 2021-2026. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in the organ transplantation, autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others.  Moreover, immunosuppressants also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis. Immunodeficiency is the major adverse effect associated with the immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects with the immunosuppressants. Immunosuppressants market is growing at a significant CAGR owing to increase in the prevalence of autoimmune disorders and incidence of organ transplantation. For instance, According to World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was increased about 1.8% from 2013. Furthermore, various pipeline products in the market also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies for increasing their revenue in immunosuppressants market. For instance, in July 2015, Veloxis Pharmaceuticals A/S received FDA approval for Envarsus XR used for the prophylaxis of rejection in the kidney transplant patients.  Moreover, in October 2016, Cadila Healthcare partnered with Neovii to launch an immunosuppressants in India market.

Immunosuppressants Market

MARKET SUMMARY
-
14.2% CAGR
  • Study Period– 2021 – 2026
  • Base Year– 2020
  • CAGR– 14.2%
  • Largest Market– North America
  • Fastest Growing Market–  Asia-Pacific

Immunosuppressants Market

  • The report on global immunosuppressants market gives historical, current and future market sizes (US$ Mn) based on drug class, indication, route of administration, distribution channel and region.
  • immunosuppressants market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • GlaxoSmithKline Plc.,
  • Novartis AG,
  • Sanofi S.A.,
  • Pfizer, Inc.,
  • Bristol Myers Squibb,
  • F. Hoffmann La Roche Ltd.,
  • Astellas Pharma, Inc.,
  • Genzyme Corporation.
Immunosuppressants Market

Drivers And Restraints

Increase in the incidence of organ failure and there by rising demand for organ transplantation, technological advancements in organ transplantation procedures, and increase in the prevalence of autoimmune diseases are the factors anticipated to fuel the immunosuppressants market over the forecast period. Moreover, favourable reimbursement policies for immunosuppressants, development of newer therapeutic drugs, and various pipeline products might fuel the immunosuppressants market over the forecast period. However, stringent regulatory policies for drug approval, alternative therapies such as stem cell therapy for immunosuppression, and lack of awareness about immunosuppressants are the factors expected to hamper the growth of immunosuppressants market over the forecast period.


North-America got significant share

Immunosuppressants Market

Geographically, immunosuppressants market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America immunosuppressants market accounted for significant share in global immunosuppressants market owing to increase in the prevalence of autoimmune disorders (according to American Autoimmune Related Disease Association in 2016, approximately 50 Mn people suffering from the autoimmune diseases), and product launchings by the market players in the U.S. market. Europe immunosuppressants market expected to exhibit significant growth owing to increase in incidence of organ transplantation (according to European Commission 2013 data, approximately 31,165 organ transplantation cases observed in EU countries), development of novel drugs, and developed healthcare infrastructure in the region. However, Asia Pacific is an emerging region for immunosuppressants market owing to rise in medical tourism due to low cost of the treatment, launching of newer products, and increase in the prevalence of autoimmune diseases are expected to bolster the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In September 2017, Zydus Cadila received FDA final approval for Mycophenolate Mofetil Immunosuppressant injection
  • In April 2017, Sanofi received FDA approval for Thymoglobulin immunosuppressant drug used for the prevention of acute kidney transplant rejection.

Key

Key Features of the Report

Immunosuppressants Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • GlaxoSmithKline Plc. (U.K.)
  • Novartis AG (Switzerland)
  • Sanofi S.A. (France)
  • Pfizer, Inc. (U.S.)
  • Bristol Myers Squibb (U.S.)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Astellas Pharma, Inc. (Japan)
  • Zydus Cadila (India)
  • Genzyme Corporation (U.S.)

Description

The global immunosuppressants market size expected to reach $41,511.37 million by 2026, at a CAGR of 14.2% during forecast period 2021-2026. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in the organ transplantation, autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others.  Moreover, immunosuppressants also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis. Immunodeficiency is the major adverse effect associated with the immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects with the immunosuppressants. Immunosuppressants market is growing at a significant CAGR owing to increase in the prevalence of autoimmune disorders and incidence of organ transplantation. For instance, According to World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was increased about 1.8% from 2013. Furthermore, various pipeline products in the market also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies for increasing their revenue in immunosuppressants market. For instance, in July 2015, Veloxis Pharmaceuticals A/S received FDA approval for Envarsus XR used for the prophylaxis of rejection in the kidney transplant patients.  Moreover, in October 2016, Cadila Healthcare partnered with Neovii to launch an immunosuppressants in India market.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX